Concurrent chemoradiotherapy for locally advanced unresectable adenoid cystic carcinoma of head and neck: experience from a single institute.


Journal

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 30 11 2020
accepted: 27 01 2021
pubmed: 11 2 2021
medline: 6 10 2021
entrez: 10 2 2021
Statut: ppublish

Résumé

To analyze the outcome of locally advanced unresectable adenoid cystic carcinoma (ACC) of head and neck treated with radical concurrent chemoradiotherapy (CRT) at a single tertiary care centre. Between 2011 and 2018, 23 patients with locally advanced unresectable ACC of head and neck treated with non-surgical radical treatment with concurrent chemoradiotherapy were evaluated for outcome and toxicity. All but one patient received cisplatin-based concurrent chemotherapy and 74% of patients were treated with intensity-modulated radiotherapy. Median follow-up was 53 months (range 3-115 months). Following treatment, 11 patients achieved complete response (47.8%) and of the 12 patients with residual disease, 7 patients additionally had disease stabilization without local progression. Overall 15 patients had disease progression. Median time to progression was 28 months (range 6-67 months). The 3-year and 5-year overall survival, local progression-free survival (LPFS) and distant progression-free survival (DPFS) were 78%, 79.7%, 67.4% and 63%, 50.9%, 48.6%, respectively. Acute grade 3 mucositis was observed in three patients, and one patient additionally developed grade 4 neutropenia with subsequent complete recovery. No grade 3 or higher late toxicity was observed. Radical concurrent chemoradiotherapy is a promising treatment option in locally advanced unresectable ACC with acceptable toxicity.

Identifiants

pubmed: 33564909
doi: 10.1007/s00405-021-06654-3
pii: 10.1007/s00405-021-06654-3
doi:

Substances chimiques

Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4423-4431

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Références

Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY, Owonikoko T, Ramalingam S, Shin DM, Khuri FR, Beitler JJ, Saba NF (2012) Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973–2007 Surveillance, Epidemiology, and End Results data. Cancer 118(18):4444–4451. https://doi.org/10.1002/cncr.27408
doi: 10.1002/cncr.27408 pubmed: 22294420
Coca-Pelaz A, Rodrigo JP, Bradley PJ, Vander Poorten V, Triantafyllou A, Hunt JL, Strojan P, Rinaldo A, Haigentz M Jr, Takes RP, Mondin V, Teymoortash A, Thompson LD, Ferlito A (2015) Adenoid cystic carcinoma of the head and neck—an update. Oral Oncol 51(7):652–661. https://doi.org/10.1016/j.oraloncology.2015.04.005
doi: 10.1016/j.oraloncology.2015.04.005 pubmed: 25943783
Amit M, Binenbaum Y, Sharma K, Ramer N, Ramer I, Agbetoba A, Miles B, Yang X, Lei D, Bjoerndal K, Godballe C, Mucke T, Wolff KD, Fliss D, Eckardt AM, Copelli C, Sesenna E, Palmer F, Patel S, Gil Z (2014) Analysis of failure in patients with adenoid cystic carcinoma of the head and neck. An international collaborative study. Head Neck 36(7):998–1004. https://doi.org/10.1002/hed.23405
doi: 10.1002/hed.23405 pubmed: 23784851
Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ (1995) The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 32(3):619–626. https://doi.org/10.1016/0360-3016(95)00122-F
doi: 10.1016/0360-3016(95)00122-F pubmed: 7790247
Cohen AN, Damrose EJ, Huang RY, Nelson SD, Blackwell KE, Calcaterra TC (2004) Adenoid cystic carcinoma of the submandibular gland: a 35-year review. Otolaryngol Head Neck Surg 131(6):994–1000. https://doi.org/10.1016/j.otohns.2004.06.705
doi: 10.1016/j.otohns.2004.06.705 pubmed: 15577803
Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Hinerman RW, Villaret DB (2004) Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 26(2):154–162. https://doi.org/10.1002/hed.10380
doi: 10.1002/hed.10380 pubmed: 14762884
Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK (2006) Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys 66(4):1044–1050. https://doi.org/10.1016/j.ijrobp.2006.06.050
doi: 10.1016/j.ijrobp.2006.06.050 pubmed: 16965870
Shen C, Xu T, Huang C, Hu C, He S (2012) Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck. Oral Oncol 48(5):445–449. https://doi.org/10.1016/j.oraloncology.2011.12.002
doi: 10.1016/j.oraloncology.2011.12.002 pubmed: 22209446
Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, van Den Ende PL, Burlage F, Dutch H, Neck Oncology Cooperative G (2005) The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61(1):103–111. https://doi.org/10.1016/j.ijrobp.2004.03.018
doi: 10.1016/j.ijrobp.2004.03.018 pubmed: 15629600
Zeidan YH, Pekelis L, An Y, Holsinger FC, Kong CS, Chang DT, Le QT (2015) Survival benefit for adjuvant radiation therapy in minor salivary gland cancers. Oral Oncol 51(5):438–445. https://doi.org/10.1016/j.oraloncology.2015.02.096
doi: 10.1016/j.oraloncology.2015.02.096 pubmed: 25771077
Agarwal JP, Jain S, Gupta T, Tiwari M, Laskar SG, Dinshaw KA, Chaturvedi P, D’Cruz AK, Shrivastava SK (2008) Intraoral adenoid cystic carcinoma: prognostic factors and outcome. Oral Oncol 44(10):986–993. https://doi.org/10.1016/j.oraloncology.2008.01.004
doi: 10.1016/j.oraloncology.2008.01.004 pubmed: 18329324
Lloyd S, Yu JB, Wilson LD, Decker RH (2011) Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am J Clin Oncol 34(1):76–81. https://doi.org/10.1097/COC.0b013e3181d26d45
doi: 10.1097/COC.0b013e3181d26d45 pubmed: 20177363
Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24(17):2673–2678. https://doi.org/10.1200/JCO.2005.05.3025
doi: 10.1200/JCO.2005.05.3025 pubmed: 16763282
Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE (2004) Adenoid cystic carcinoma of the head and neck—a 20 years experience. Int J Oral Maxillofac Surg 33(1):25–31. https://doi.org/10.1054/ijom.2003.0448
doi: 10.1054/ijom.2003.0448 pubmed: 14690656
Adelstein DJ, Koyfman SA, El-Naggar AK, Hanna EY (2012) Biology and management of salivary gland cancers. Semin Radiat Oncol 22(3):245–253. https://doi.org/10.1016/j.semradonc.2012.03.009
doi: 10.1016/j.semradonc.2012.03.009 pubmed: 22687949
Cowie VJ, Pointon RC (1984) Adenoid cystic carcinoma of the salivary glands. Clin Radiol 35(4):331–333
doi: 10.1016/S0009-9260(84)80116-6
Matsuba HM, Thawley SE, Simpson JR, Levine LA, Mauney M (1984) Adenoid cystic carcinoma of major and minor salivary gland origin. Laryngoscope 94(10):1316–1318
doi: 10.1288/00005537-198410000-00011
Vikram B, Strong EW, Shah JP, Spiro RH (1984) Radiation therapy in adenoid-cystic carcinoma. Int J Radiat Oncol Biol Phys 10(2):221–223
doi: 10.1016/0360-3016(84)90007-5
Miglianico L, Eschwege F, Marandas P, Wibault P (1987) Cervico-facial adenoid cystic carcinoma: study of 102 cases. Influence of radiation therapy. Int J Radiat Oncol Biol Phys 13(5):673–678
doi: 10.1016/0360-3016(87)90284-7
Iseli TA, Karnell LH, Graham SM, Funk GF, Buatti JM, Gupta AK, Robinson RA, Hoffman HT (2009) Role of radiotherapy in adenoid cystic carcinoma of the head and neck. J Laryngol Otol 123(10):1137–1144. https://doi.org/10.1017/S0022215109990338
doi: 10.1017/S0022215109990338 pubmed: 19573256
Douglas JG, Laramore GE, Austin-Seymour M, Koh W, Stelzer K, Griffin TW (2000) Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 46(3):551–557
doi: 10.1016/S0360-3016(99)00445-9
Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, Engenhart-Cabillic R (2001) Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol 59(2):161–167
doi: 10.1016/S0167-8140(00)00273-5
Pommier P, Liebsch NJ, Deschler DG, Lin DT, McIntyre JF, Barker FG 2nd, Adams JA, Lopes VV, Varvares M, Loeffler JS, Chan AW (2006) Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg 132(11):1242–1249. https://doi.org/10.1001/archotol.132.11.1242
doi: 10.1001/archotol.132.11.1242 pubmed: 17116822
Takagi M, Demizu Y, Hashimoto N, Mima M, Terashima K, Fujii O, Jin D, Niwa Y, Morimoto K, Akagi T, Daimon T, Sasaki R, Hishikawa Y, Abe M, Murakami M, Fuwa N (2014) Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck. Radiother Oncol 113(3):364–370. https://doi.org/10.1016/j.radonc.2014.11.031
doi: 10.1016/j.radonc.2014.11.031 pubmed: 25467004
Linton OR, Moore MG, Brigance JS, Summerlin DJ, McDonald MW (2015) Proton therapy for head and neck adenoid cystic carcinoma: initial clinical outcomes. Head Neck 37(1):117–124
doi: 10.1002/hed.23573
Sulaiman NS, Demizu Y, Koto M, Saitoh JI, Suefuji H, Tsuji H, Ohno T, Shioyama Y, Okimoto T, Daimon T, Nemoto K, Nakano T, Kamada T, Japan Carbon-Ion Radiation Oncology Study G (2018) Multicenter study of carbon-ion radiation therapy for adenoid cystic carcinoma of the head and neck: subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys 100(3):639–646. https://doi.org/10.1016/j.ijrobp.2017.11.010
doi: 10.1016/j.ijrobp.2017.11.010 pubmed: 29413278
Maruya S, Namba A, Matsubara A, Kakehata S, Takeda I, Shirasaki T, Hatayama Y, Nagahata M, Yokoyama J, Shinkawa H (2006) Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol 11(5):403–406. https://doi.org/10.1007/s10147-006-0587-0
doi: 10.1007/s10147-006-0587-0 pubmed: 17058139
Haddad RI, Posner MR, Busse PM, Norris CM Jr, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB (2006) Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol 29(2):153–157. https://doi.org/10.1097/01.coc.0000203756.36866.17
doi: 10.1097/01.coc.0000203756.36866.17 pubmed: 16601434
Gomez DR, Hoppe BS, Wolden SL, Zhung JE, Patel SG, Kraus DH, Shah JP, Ghossein RA, Lee NY (2008) Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience. Int J Radiat Oncol Biol Phys 70(5):1365–1372. https://doi.org/10.1016/j.ijrobp.2007.08.008
doi: 10.1016/j.ijrobp.2007.08.008 pubmed: 18029108
Samant S, van den Brekel MW, Kies MS, Wan J, Robbins KT, Rosenthal DI, Rasch C, Weber RS (2012) Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head Neck 34(9):1263–1268. https://doi.org/10.1002/hed.21905
doi: 10.1002/hed.21905 pubmed: 22083968
Ha H, Keam B, Ock CY, Kim TM, Kim JH, Chung EJ, Kwon SK, Ahn SH, Wu HG, Sung MW, Heo DS (2020) Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma. Korean J Intern Med. https://doi.org/10.3904/kjim.2019.104
doi: 10.3904/kjim.2019.104 pubmed: 33147905 pmcid: 7652647
Bhattasali O, Holliday E, Kies MS, Hanna EY, Garden AS, Rosenthal DI, Morrison WH, Gunn GB, Fuller CD, Zhu XR, Frank SJ (2016) Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: a series of 9 cases and a critical review of the literature. Head Neck 38(Suppl 1):E1472-1480. https://doi.org/10.1002/hed.24262
doi: 10.1002/hed.24262 pubmed: 26561041
Perzin KH, Gullane P, Clairmont AC (1978) Adenoid cystic carcinomas arising in salivary glands: a correlation of histologic features and clinical course. Cancer 42(1):265–282. https://doi.org/10.1002/1097-0142(197807)42:1%3c265::aid-cncr2820420141%3e3.0.co;2-z
doi: 10.1002/1097-0142(197807)42:1<265::aid-cncr2820420141>3.0.co;2-z pubmed: 208752
Szanto PA, Luna MA, Tortoledo ME, White RA (1984) Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer 54(6):1062–1069. https://doi.org/10.1002/1097-0142(19840915)54:6%3c1062::aid-cncr2820540622%3e3.0.co;2-e
doi: 10.1002/1097-0142(19840915)54:6<1062::aid-cncr2820540622>3.0.co;2-e pubmed: 6088017
Balamucki CJ, Amdur RJ, Werning JW, Vaysberg M, Morris CG, Kirwan JM, Mendenhall WM (2012) Adenoid cystic carcinoma of the head and neck. Am J Otolaryngol 33(5):510–518. https://doi.org/10.1016/j.amjoto.2011.11.006
doi: 10.1016/j.amjoto.2011.11.006 pubmed: 22226227
Laramore GE, Krall JM, Griffin TW, Duncan W, Richter MP, Saroja KR, Maor MH, Davis LW (1993) Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 27(2):235–240
doi: 10.1016/0360-3016(93)90233-L
Spratt DE, Salgado LR, Riaz N, Doran MG, Tam M, Wolden S, Katsoulakis E, Rao S, Ho A, Wong R, Lee NY (2014) Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy’s local control superior? Radiol Oncol 48(1):56–61. https://doi.org/10.2478/raon-2013-0046
doi: 10.2478/raon-2013-0046 pubmed: 24587780 pmcid: 3908848
Jensen AD, Nikoghosyan AV, Lossner K, Haberer T, Jakel O, Munter MW, Debus J (2015) COSMIC: a regimen of intensity modulated radiation therapy plus dose-escalated, raster-scanned carbon ion boost for malignant salivary gland tumors: results of the prospective phase 2 trial. Int J Radiat Oncol Biol Phys 93(1):37–46. https://doi.org/10.1016/j.ijrobp.2015.05.013
doi: 10.1016/j.ijrobp.2015.05.013 pubmed: 26279022

Auteurs

Monali Swain (M)

Department of Radiation Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Dr. E. Borges Road, Parel, Mumbai, Maharashtra, 400012, India. drmonaliswain@gmail.com.

Sarbani Ghosh-Laskar (S)

Department of Radiation Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Dr. E. Borges Road, Parel, Mumbai, Maharashtra, 400012, India.

Ashwini Budrukkar (A)

Department of Radiation Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Dr. E. Borges Road, Parel, Mumbai, Maharashtra, 400012, India.

Roshan Patil (R)

Department of Radiation Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Dr. E. Borges Road, Parel, Mumbai, Maharashtra, 400012, India.

Vedang Murthy (V)

Department of Radiation Oncology, Advanced Centre for Treatment Research and Education for Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.

Tejpal Gupta (T)

Department of Radiation Oncology, Advanced Centre for Treatment Research and Education for Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.

Naveen Mummudi (N)

Department of Radiation Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Dr. E. Borges Road, Parel, Mumbai, Maharashtra, 400012, India.

Kumar Prabhash (K)

Department of Medical Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.

Amit Joshi (A)

Department of Medical Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.

Vijay Maruti Patil (VM)

Department of Medical Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.

Vanita Naronha (V)

Department of Medical Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.

Jai Prakash Agarwal (JP)

Department of Radiation Oncology, Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Dr. E. Borges Road, Parel, Mumbai, Maharashtra, 400012, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH